Interview with Tim Rolfe
Risk-based monitoring plays an increasingly important role for clinical trials. Of course, the assessment of the risk is based on statistics. This presents now only interesting career options for statisticians, but also has an impact on the role of statisticians in study teams.
In this episode, we’ll give you an introduction to risk-based monitoring (RBM) as well as speak about the role of statisticians in this area. Further we provide you as a study statistician insights into what you need to know about RBM. Finally, we also give some recommendations in terms of further resources to learn from.
About Tim Rolfe
Tim Rolfe has over 20 years of experience working as a statistician at in the pharmaceutical industry. He is currently Director of Risk Based Monitoring at GlaxoSmithKline R&D.
He has been part of GSKs RBM team since 2013, providing statistical leadership in the development and implementation of GSK’s RBM strategy within clinical trials.
Useful references
ICH E6-R2 – Good Clinical Practice:
FDA Guidelines:
Guidance for Industry Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring.
EMEA Guidelines:
Reflection paper on risk based quality management in clinical trials.
TransCelerate:
Position Paper: Risk-Based Monitoring Methodology.
Central Statistical Monitoring:
Buyse, M, George, SL, Evans, S. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Stat Med 1999; 18: 3435–51.
Baigent, C, Harrell, FE, Buyse, M, Emberson, JR, Altman, DG. Ensuring trial validity by data quality assurance and diversification of monitoring methods. Clin Trials 2008; 5: 49–55.
Kirkwood, A. A., Cox, T., & Hackshaw, A. Application of methods for central statistical monitoring in clinical trials. Clinl Trials 2013;10(5), 783–806.
Never miss an episode!
Join thousends of your peers and subscribe to get our latest updates by email!
Get the